Future Directions in HR+ Breast Cancer Management
Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.
Clinical and Practical Implications of the Breast Cancer Index
A review of when to use the Breast Cancer Index for patients with HR+ breast cancer when deciding on endocrine therapy duration.
Biomarkers for Selection of Extended Endocrine Therapy in HR+ Breast Cancer
Experts discuss biomarkers used to determine if a patient with HR+ breast cancer will benefit from extended endocrine therapy.
Data on Extended Adjuvant Endocrine Therapy in HR+ Breast Cancer
Lee Schwartzberg, MD, FACP, explains the IDEAL study and data on the benefits of extended adjuvant endocrine therapy in HR+ breast cancer.
Ordering Additional Multigene Assays for Patients with HR+ Breast Cancer
Drs Schwartzberg and Pegram debate the value of having patients undergo more than 1 multigene assay to predict their risk of recurrence.
Tools to Guide Treatment Decision-Making in HR+ Breast Cancer
Mark Pegram, MD, details the role of biomarkers in predicting recurrences in patients with HR+ breast cancer.
Optimizing Management of HR+/HER2- BC: Future Directions in Care
Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.
Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition
Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.
Considerations for Use of ADCs in HER2-Low Breast Cancer
A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.
Recurrence Patterns in Early-Stage HR+ Breast Cancer
Drs Mark Pegram and Lee Schwartzberg examine late recurrence patterns in patients with HR+ breast cancer.
Updated Guidelines for the Management of HR+ Breast Cancer
Experts highlight some important and surprising updates in the ASCO guidelines for the management of HR+ breast cancer.
ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04
Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.
Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer
Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.
Measuring Ki-67 Levels to Inform HR+ Breast Cancer Treatment
Lee Schwartzberg, MD, FACP, explains how Ki-67 is measured and used to inform management strategies for HR+ breast cancer at his clinical practice.
The Evolution of Early-Stage HR+ Breast Cancer Management
Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, discuss how the management of early-stage HR+ breast cancer has changed over time.
Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors
Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.
Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs
A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.
HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?
Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.
Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer
Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.
Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?
Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.
Frontline Combination Strategies in HR+/HER2- BC
A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.
Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer
Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v
HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition
Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.
HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting
Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.
CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib
Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.
CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib
Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.
Frontline Treatment Strategies for HR+/HER2- Breast Cancer
Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.
ESMO 2021: Updates in Triple Negative Breast Cancer
Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.
Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial
Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.
Interesting Trials in HER2+ Breast Cancer
Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.
Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL
MRD-Guided Ibrutinib Plus Venetoclax Improves Survival in Treatment-Naive CLL
Retrospective Analysis Supports Utilization of Auto-HCT in Relapsed LBCL Achieving a CR
Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden
2 Clarke Drive Cranbury, NJ 08512